At J.P. Morgan, Ironwood, Shire and Biogen Idec Contemplate What’s Next

A trio of companies offer insight into their latest strategies from interviews and presentations at the recent J.P. Morgan Healthcare conference: Ironwood’s development pipeline includes seven GI drugs; R&D consolidation and pipeline review at Shire; Biogen preps for hemophilia market and MS pricing pressures.